Indeed, PD-L1 is expressed at higher levels in KRASG12D,G12V,G13C mutated cancers and at lower levels within KRASG12A and G12C mutated cancers (102), suggesting that different KRAS mutations confers to the mutated protein higher or lower ability to influence downstream signalling pathways that then shapes the TME. Here, KRAS is linked to cancer.